Teriparatide (1-34 human PTH) regulation of osterix during fracture repair

Journal of Cellular Biochemistry

Volumn 105, Issue 1, 2008, Pages 219-226

  Kaback, Lee A ^a   Soung, Do Y ^b   Naik, Amish ^a   Geneau, Graziello ^b   Schwarz, Edward M ^a   Rosier, Randy N ^a   O'Keefe, Regis J ^a   Drissi, Hicham ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Fractures; Osterix SP7; PTH; Runx2; Teriparatide

Indexed keywords

ALKALINE PHOSPHATASE; BETA ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE REGENERATION; CALLUS; CARTILAGE CELL; CONTROLLED STUDY; FEMUR; FRACTURE; FRACTURE HEALING; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIBIA; X RAY;

ANIMALS; BIOLOGICAL MARKERS; BONE MARROW; CELL DIFFERENTIATION; CELLS, CULTURED; FRACTURE HEALING; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OSTEOBLASTS; PHENOTYPE; STEM CELLS; TERIPARATIDE; TRANSCRIPTION FACTORS;

ANIMALIA; MUS;

EID: 51849095384     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21816     Document Type: Article

References (39)

1. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA. 2005. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87:731-741.
2. Andreassen TT, Ejersted C, Oxlund H. 1999. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960-968.
3. Andreassen TT, Willick GE, Morley P, Whitfield JF. 2004. Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 74:351-356.
4. Arnaud CD, Tsao HS, Oldham SB. 1970. Native human parathyroid hormone: An immunochemical investigation. Proc Natl Acad Sci USA 67:415-422.
5. Bilezikian JP, Rubin MR, Finkelstein JS. 2005. Parathyroid hormone as an anabolic therapy for women and men. J Endocrinol Invest 28:41-49.
6. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. 2003. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
7. Bonnarens F, Einhorn TA. 1984. Production of a standard closed fracture in laboratory animal bone. J Orthop Res 2:97-101.
8. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23:524-528.
9. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R. 2001. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
10. Drissi H, Hushka D, Aslam F, Nguyen Q, Buffone E, Koff A, van Wijnen A, Lian JB, Stein JL, Stein GS. 1999. The cell cycle regulator p27kip 1 contributes to growth and differentiation of osteoblasts. Cancer Res 59:3705-3711.
11. Ferguson C, Alpern E, Miclau T, Helms JA. 1999. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 87:57-66.
12. Finkelstein JS. 2000. Osteoporosis. In: Cecil RL, Bennett JC, Goldman L, editors. Cecil textbook of medicine. 21st edition. Philadelphia, PA: WB Saunders & Co.
13. Gerstenfeld LC, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. 2003. Fracture healing as a post-natal developmental process: Molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88:873-884.
14. Hadjidakis DJ, Androulakis II. 2006. Bone remodeling. Ann NY Acad Sci 1092:385-396.
15. Heaney RP. 2003. Advances in therapy for osteoporosis. Clin Med Res 1:93-99.
16. Hiltunen A, Vuorio E, Aro HT. 1993. A standardized experimental fracture in the mouse tibia. J Orthop Res 11:305-312.
17. Hock JM, Gera I. 1992. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65-72.
18. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A. 1997. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99:2961-2970.
19. Jiang Y, Zhao J, Liao EY, Dai RC, Wu XP, Genant HK. 2005. Application of micro-CT assessment of 3-D bone microstructure in preclinical and clinical studies. J Bone Miner Metab 23(Suppl):122-131.
20. Kaback LA, Soung dY, Naik A, Smith N, Schwarz EM, O'Keefe RJ, Drissi H. 2008. Osterix/Sp7 regulates mesenchymal stem cell mediated endochondral ossification. J Cell Physiol 214:173-182.
21. Krishnan V, Moore TL, Ma YL, Helvering LM, Frolik CA, Valasek KM, Ducy P, Geiser AG. 2003. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol 17:423-435.
22. Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, N'cho M, Sterchi DL, Gitter BD, Higgs RE, Halladay DL, Engler TA, Martin TJ, Bryant HU, Ma YL, Onyia JE. 2007. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem 102:1504-1518.
23. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. 2000. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076.
24. Lee MH, Kwon TG, Park HS, Wozney JM, Ryoo HM. 2003. BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem Biophys Res Commun 309:689-694.
25. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29.
26. Nakashima K, de Crombrugghe B. 2003. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet 19:458-466.
27. Nakazawa T, Nakajima A, Shiomi K, Moriya H, Einhorn TA, Yamazaki M. 2005. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 37:711-719.
28. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
29. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, Suda T, Yoshiki S, Takahashi HE. 1994. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15:717-723.
30. Nishio Y, Dong Y, Paris M, O'Keefe RJ, Schwarz EM, Drissi H. 2006. Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene. Gene 372:62-70.
31. Potts JT. 2005. Parathyroid hormone: Past and present. J Endocrinol 187:311-325.
32. Riggs BL, Melton LJ III. 1995. The worldwide problem of osteoporosis: Insights afforded by epidemiology. Bone 17:505S-511S.
33. Rodan GA, Martin TJ. 2000. Therapeutic approaches to bone diseases. Science 289:1508-1514.
34. Soung dY, Dong Y, Wang Y, Zuscik MJ, Schwarz EM, O'Keefe RJ, Drissi H. 2007. Runx3/AML2/Cbfa3 regulates early and late chondrocyte differentiation. J Bone Miner Res 22:1260-1270.
35. Thomas T. 2006. Intermittent parathyroid hormone therapy to increase bone formation. Joint Bone Spine 73:262-269.
36. Tu Q, Valverde P, Chen J. 2006. Osterix enhances proliferation and osteogenic potential of bone marrow stromal cells. Biochem Biophys Res Commun 341:1257-1265.
37. van der HG, Farih-Sips H, Lowik CW, Karperien M. 2005. Multiple mechanisms are involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 Cells. J Bone Miner Res 20:2233-2244.
38. Vortkamp A, Pathi S, Peretti GM, Caruso EM, Zaleske DJ, Tabin CJ. 1998. Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech Dev 71:65-76.
39. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. 2002. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405-1415.